Skip to main content
Top
Published in: Diabetologia 10/2009

01-10-2009 | Article

Constitutive expression of suppressor of cytokine signalling-3 in skeletal muscle leads to reduced mobility and overweight in mice

Authors: P. Lebrun, E. Cognard, R. Bellon-Paul, P. Gontard, C. Filloux, C. Jehl-Pietri, P. Grimaldi, M. Samson, L. Pénicaud, J. Ruberte, T. Ferre, A. Pujol, F. Bosch, E. Van Obberghen

Published in: Diabetologia | Issue 10/2009

Login to get access

Abstract

Aims/hypothesis

Due to their ability to regulate various signalling pathways (cytokines, hormones, growth factors), the suppressor of cytokine signalling (SOCS) proteins are thought to be promising therapeutic targets for metabolic and inflammatory disorders. Hence, their role in vivo has to be precisely determined.

Methods

We generated transgenic mice constitutively producing SOCS-3 in skeletal muscle to define whether the sole abundance of SOCS-3 is sufficient to induce metabolic disorders and whether SOCS-3 is implicated in physiological roles distinct from metabolism.

Results

We demonstrate here that chronic expression of SOCS-3 in skeletal muscle leads to overweight in mice and worsening of high-fat diet-induced systemic insulin resistance. Counter-intuitively, insulin sensitivity in muscle of transgenic mice appears to be unaltered. However, following constitutive SOCS-3 production, several genes had deregulated expression, among them other members of the SOCS family. This could maintain the insulin signal into skeletal muscle. Interestingly, we found that SOCS-3 interacts with calcineurin, which has been implicated in muscle contractility. In Socs-3 transgenic muscle, this leads to delocalisation of calcineurin to the fibre periphery. Relevant to this finding, Socs-3 transgenic animals had dilatation of the sarcoplasmic reticulum associated with swollen mitochondria and decreased voluntary activity.

Conclusions/interpretation

Our results show that constitutive SOCS-3 production in skeletal muscle is not in itself sufficient to induce the establishment of metabolic disorders such as diabetes. In contrast, we reveal a novel role of SOCS-3, which appears to be important for muscle integrity and locomotor activity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fujimoto M, Naka T (2003) Regulation of cytokine signalling by SOCS family molecules. Trends Immunol 24:659–666PubMedCrossRef Fujimoto M, Naka T (2003) Regulation of cytokine signalling by SOCS family molecules. Trends Immunol 24:659–666PubMedCrossRef
2.
go back to reference Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275:15985–15991PubMedCrossRef Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275:15985–15991PubMedCrossRef
3.
go back to reference Ueki K, Kondo T, Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434–5446PubMedCrossRef Ueki K, Kondo T, Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434–5446PubMedCrossRef
4.
go back to reference Rui L, Yuan M, Frantz D, Shoelson S, White MF (2002) SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277:42394–42398PubMedCrossRef Rui L, Yuan M, Frantz D, Shoelson S, White MF (2002) SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277:42394–42398PubMedCrossRef
5.
go back to reference Bjorbak C, Lavery HJ, Bates SH et al (2000) SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem 275:40649–40657PubMedCrossRef Bjorbak C, Lavery HJ, Bates SH et al (2000) SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem 275:40649–40657PubMedCrossRef
6.
go back to reference Dunn SL, Bjornholm M, Bates SH, Chen Z, Seifert M, Myers MG (2005) Feedback inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin receptor and suppressor of cytokine signaling 3. Mol Endocrinol 19:925–938PubMedCrossRef Dunn SL, Bjornholm M, Bates SH, Chen Z, Seifert M, Myers MG (2005) Feedback inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin receptor and suppressor of cytokine signaling 3. Mol Endocrinol 19:925–938PubMedCrossRef
7.
go back to reference Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Bjorbaek C, Flier JS (2004) Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 10:734–738PubMedCrossRef Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Bjorbaek C, Flier JS (2004) Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 10:734–738PubMedCrossRef
8.
go back to reference Kievit P, Howard JK, Badman MK et al (2006) Enhanced leptin sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells. Cell Metab 4:123–132PubMedCrossRef Kievit P, Howard JK, Badman MK et al (2006) Enhanced leptin sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells. Cell Metab 4:123–132PubMedCrossRef
9.
go back to reference Ueki K, Kadowaki T, Kahn CR (2005) Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res 33:185–192PubMedCrossRef Ueki K, Kadowaki T, Kahn CR (2005) Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res 33:185–192PubMedCrossRef
10.
go back to reference Ueki K, Kondo T, Tseng YH, Kahn CR (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A 101:10422–10427PubMedCrossRef Ueki K, Kondo T, Tseng YH, Kahn CR (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A 101:10422–10427PubMedCrossRef
11.
go back to reference Shi H, Cave B, Inouye K, Bjorbaek C, Flier JS (2006) Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance. Diabetes 55:699–707PubMedCrossRef Shi H, Cave B, Inouye K, Bjorbaek C, Flier JS (2006) Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance. Diabetes 55:699–707PubMedCrossRef
12.
go back to reference Lindberg K, Ronn SG, Tornehave D et al (2005) Regulation of pancreatic beta-cell mass and proliferation by SOCS-3. J Mol Endocrinol 35:231–243PubMedCrossRef Lindberg K, Ronn SG, Tornehave D et al (2005) Regulation of pancreatic beta-cell mass and proliferation by SOCS-3. J Mol Endocrinol 35:231–243PubMedCrossRef
13.
go back to reference Ronn SG, Börjesson A, Bruun C et al (2008) Suppressor of cytokine signalling-3 expression inhibits cytokine-mediated destruction of primary mouse and rat pancreatic islets and delays allograft rejection. Diabetologia 51:1873–1882PubMedCrossRef Ronn SG, Börjesson A, Bruun C et al (2008) Suppressor of cytokine signalling-3 expression inhibits cytokine-mediated destruction of primary mouse and rat pancreatic islets and delays allograft rejection. Diabetologia 51:1873–1882PubMedCrossRef
14.
15.
go back to reference Spangenburg EE, Brown DA, Johnson MS, Moore RL (2006) Exercise increases SOCS-3 expression in rat skeletal muscle: potential relationship to IL-6 expression. J Physiol 572:839–848PubMed Spangenburg EE, Brown DA, Johnson MS, Moore RL (2006) Exercise increases SOCS-3 expression in rat skeletal muscle: potential relationship to IL-6 expression. J Physiol 572:839–848PubMed
16.
go back to reference Fasshauer M, Klein J, Lossner U, Paschke R (2002) Isoproterenol is a positive regulator of the suppressor of cytokine signaling-3 gene expression in 3T3–L1 adipocytes. J Endocrinol 175:727–733PubMedCrossRef Fasshauer M, Klein J, Lossner U, Paschke R (2002) Isoproterenol is a positive regulator of the suppressor of cytokine signaling-3 gene expression in 3T3–L1 adipocytes. J Endocrinol 175:727–733PubMedCrossRef
17.
go back to reference Banerjee A, Banks AS, Nawijn MC, Chen XP, Rothman PB (2002) Cutting edge: suppressor of cytokine signaling 3 inhibits activation of NFATp. J Immunol 168:4277–4281PubMed Banerjee A, Banks AS, Nawijn MC, Chen XP, Rothman PB (2002) Cutting edge: suppressor of cytokine signaling 3 inhibits activation of NFATp. J Immunol 168:4277–4281PubMed
18.
go back to reference Shin DW, Pan Z, Bandyopadhyay A, Bhat MB, Kim DH, Ma J (2002) Ca(2+)-dependent interaction between FKBP12 and calcineurin regulates activity of the Ca(2+) release channel in skeletal muscle. Biophys J 83:2539–2549PubMedCrossRef Shin DW, Pan Z, Bandyopadhyay A, Bhat MB, Kim DH, Ma J (2002) Ca(2+)-dependent interaction between FKBP12 and calcineurin regulates activity of the Ca(2+) release channel in skeletal muscle. Biophys J 83:2539–2549PubMedCrossRef
19.
go back to reference Rosenthal N, Kornhauser JM, Donoghue M, Rosen KM, Merlie JP (1989) Myosin light chain enhancer activates muscle-specific, developmentally regulated gene expression in transgenic mice. Proc Natl Acad Sci U S A 86:7780–7784PubMedCrossRef Rosenthal N, Kornhauser JM, Donoghue M, Rosen KM, Merlie JP (1989) Myosin light chain enhancer activates muscle-specific, developmentally regulated gene expression in transgenic mice. Proc Natl Acad Sci U S A 86:7780–7784PubMedCrossRef
20.
go back to reference Otaegui PJ, Ferre T, Riu E, Bosch F (2003) Prevention of obesity and insulin resistance by glucokinase expression in skeletal muscle of transgenic mice. FASEB J 17:2097–2099PubMed Otaegui PJ, Ferre T, Riu E, Bosch F (2003) Prevention of obesity and insulin resistance by glucokinase expression in skeletal muscle of transgenic mice. FASEB J 17:2097–2099PubMed
21.
go back to reference Heydrick SJ, Jullien D, Gautier N et al (1993) Defect in skeletal muscle phosphatidylinositol-3-kinase in obese insulin-resistant mice. J Clin Invest 91:1358–1366PubMedCrossRef Heydrick SJ, Jullien D, Gautier N et al (1993) Defect in skeletal muscle phosphatidylinositol-3-kinase in obese insulin-resistant mice. J Clin Invest 91:1358–1366PubMedCrossRef
22.
go back to reference Hinault C, Mothe-Satney I, Gautier N, Lawrence JC Jr, Van Obberghen E (2004) Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/db mice. FASEB J 18:1894–1896PubMed Hinault C, Mothe-Satney I, Gautier N, Lawrence JC Jr, Van Obberghen E (2004) Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/db mice. FASEB J 18:1894–1896PubMed
23.
go back to reference Smyth GK, Michaud J, Scott H (2005) The use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21:2067–2075PubMedCrossRef Smyth GK, Michaud J, Scott H (2005) The use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21:2067–2075PubMedCrossRef
24.
go back to reference Cayatte C, Pons C, Guigonis JM et al (2006) Protein profiling of rat ventral prostate following chronic finasteride administration: identification and localization of a novel putative androgen-regulated protein. Mol Cell Proteomics 5:2031–2043PubMedCrossRef Cayatte C, Pons C, Guigonis JM et al (2006) Protein profiling of rat ventral prostate following chronic finasteride administration: identification and localization of a novel putative androgen-regulated protein. Mol Cell Proteomics 5:2031–2043PubMedCrossRef
25.
go back to reference Luquet S, Lopez-Soriano J, Holst D et al (2003) Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J 17:2299–2301PubMed Luquet S, Lopez-Soriano J, Holst D et al (2003) Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J 17:2299–2301PubMed
26.
go back to reference Bauche IB, El Mkadem SA, Pottier AM et al (2007) Overexpression of Adiponectin targeted to adipose tissue in transgenic mice: impaired adipocyte differentiation. Endocrinology 148:1539–1549PubMedCrossRef Bauche IB, El Mkadem SA, Pottier AM et al (2007) Overexpression of Adiponectin targeted to adipose tissue in transgenic mice: impaired adipocyte differentiation. Endocrinology 148:1539–1549PubMedCrossRef
27.
go back to reference Naya FJ, Mercer B, Shelton J, Richardson JA, Williams RS, Olson EN (2007) Calcineurin regulates skeletal muscle metabolism via coordinated changes in gene expression. J Biol Chem 282:1607–1614 Naya FJ, Mercer B, Shelton J, Richardson JA, Williams RS, Olson EN (2007) Calcineurin regulates skeletal muscle metabolism via coordinated changes in gene expression. J Biol Chem 282:1607–1614
28.
go back to reference Long YC, Glund S, Garcia-Roves PM, Zierath JR (2000) Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo. J Biol Chem 275:4545–4548CrossRef Long YC, Glund S, Garcia-Roves PM, Zierath JR (2000) Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo. J Biol Chem 275:4545–4548CrossRef
29.
go back to reference Torgan CE, Daniels MP (2006) Calcineurin localization in skeletal muscle offers insights into potential new targets. J Histochem Cytochem 54:119–128PubMedCrossRef Torgan CE, Daniels MP (2006) Calcineurin localization in skeletal muscle offers insights into potential new targets. J Histochem Cytochem 54:119–128PubMedCrossRef
30.
go back to reference Long YC, Zierath JR (2008) Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle. Am J Physiol Endocrinol Metab 295:E545–E552PubMedCrossRef Long YC, Zierath JR (2008) Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle. Am J Physiol Endocrinol Metab 295:E545–E552PubMedCrossRef
31.
go back to reference Emanuelli B, Peraldi P, Filloux C et al (2001) SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 276:47944–47949PubMed Emanuelli B, Peraldi P, Filloux C et al (2001) SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 276:47944–47949PubMed
32.
go back to reference Rieusset J, Bouzakri K, Chevillotte E et al (2004) Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 53:2232–2241PubMedCrossRef Rieusset J, Bouzakri K, Chevillotte E et al (2004) Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 53:2232–2241PubMedCrossRef
33.
go back to reference Gylvin T, Nolsoe R, Hansen T et al (2004) Mutation analysis of suppressor of cytokine signalling 3, a candidate gene in type 1 diabetes and insulin sensitivity. Diabetologia 47:1273–1277PubMedCrossRef Gylvin T, Nolsoe R, Hansen T et al (2004) Mutation analysis of suppressor of cytokine signalling 3, a candidate gene in type 1 diabetes and insulin sensitivity. Diabetologia 47:1273–1277PubMedCrossRef
34.
go back to reference Metcalf D, Greenhalgh CJ, Viney E et al (2000) Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405:1069–1073PubMedCrossRef Metcalf D, Greenhalgh CJ, Viney E et al (2000) Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405:1069–1073PubMedCrossRef
35.
go back to reference González L, Miquet JG, Sotelo AI, Bartke A, Turyn D (2002) Cytokine-inducible SH2 protein up-regulation is associated with desensitization of GH signaling in GHRH-transgenic mice. Endocrinology 143:386–394PubMedCrossRef González L, Miquet JG, Sotelo AI, Bartke A, Turyn D (2002) Cytokine-inducible SH2 protein up-regulation is associated with desensitization of GH signaling in GHRH-transgenic mice. Endocrinology 143:386–394PubMedCrossRef
36.
go back to reference Chavey C, Lazennec G, Lagarrigue S et al (2009) CXC Ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metabolism 9:339–349PubMedCrossRef Chavey C, Lazennec G, Lagarrigue S et al (2009) CXC Ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metabolism 9:339–349PubMedCrossRef
37.
go back to reference Piessevaux J, Lavens D, Montoye T et al (2006) Functional cross-modulation between SOCS proteins can stimulate cytokine signaling. J Biol Chem 281:32953–32966PubMedCrossRef Piessevaux J, Lavens D, Montoye T et al (2006) Functional cross-modulation between SOCS proteins can stimulate cytokine signaling. J Biol Chem 281:32953–32966PubMedCrossRef
38.
go back to reference Watt MJ, Hevener A, Lancaster GI, Febbraio MA (2006) Ciliary neurotrophic factor prevents acute lipid-induced insulin resistance by attenuating ceramide accumulation and phosphorylation of c-Jun N-terminal kinase in peripheral tissues. Endocrinology 147:2077–2085PubMedCrossRef Watt MJ, Hevener A, Lancaster GI, Febbraio MA (2006) Ciliary neurotrophic factor prevents acute lipid-induced insulin resistance by attenuating ceramide accumulation and phosphorylation of c-Jun N-terminal kinase in peripheral tissues. Endocrinology 147:2077–2085PubMedCrossRef
39.
go back to reference Watt MJ, Dzamko N, Thomas WG et al (2006) CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 12:541–548PubMedCrossRef Watt MJ, Dzamko N, Thomas WG et al (2006) CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 12:541–548PubMedCrossRef
40.
go back to reference Wang H, Knaub LA, Jensen DR et al (2009) Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues. Diabetes 58:116–124PubMedCrossRef Wang H, Knaub LA, Jensen DR et al (2009) Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues. Diabetes 58:116–124PubMedCrossRef
41.
go back to reference Bigard X, Sanchez H, Zoll J et al (2000) Calcineurin co-regulates contractile and metabolic components of slow muscle phenotype. J Biol Chem 275:19653–19660PubMedCrossRef Bigard X, Sanchez H, Zoll J et al (2000) Calcineurin co-regulates contractile and metabolic components of slow muscle phenotype. J Biol Chem 275:19653–19660PubMedCrossRef
42.
go back to reference Swoap SJ, Hunter RB, Stevenson EJ et al (2000) The calcineurin-NFAT pathway and muscle fiber-type gene expression. Am J Physiol Cell Physiol 279:C915–C924PubMed Swoap SJ, Hunter RB, Stevenson EJ et al (2000) The calcineurin-NFAT pathway and muscle fiber-type gene expression. Am J Physiol Cell Physiol 279:C915–C924PubMed
43.
go back to reference Parsons SA, Wilkins BJ, Bueno OF, Molkentin JD (2003) Altered skeletal muscle phenotypes in calcineurin Aalpha and Abeta gene-targeted mice. Mol Cell Biol 23:4331–4343PubMedCrossRef Parsons SA, Wilkins BJ, Bueno OF, Molkentin JD (2003) Altered skeletal muscle phenotypes in calcineurin Aalpha and Abeta gene-targeted mice. Mol Cell Biol 23:4331–4343PubMedCrossRef
44.
go back to reference Rossi AE, Dirksen RT (2006) Sarcoplasmic reticulum: the dynamic calcium governor of muscle. Muscle Nerve 33:715–731PubMedCrossRef Rossi AE, Dirksen RT (2006) Sarcoplasmic reticulum: the dynamic calcium governor of muscle. Muscle Nerve 33:715–731PubMedCrossRef
45.
go back to reference Bellinger AM, Reiken S, Dura M et al (2008) Remodeling of ryanodine receptor complex causes "leaky" channels: a molecular mechanism for decreased exercise capacity. Proc Natl Acad Sci U S A 105:2198–2202PubMedCrossRef Bellinger AM, Reiken S, Dura M et al (2008) Remodeling of ryanodine receptor complex causes "leaky" channels: a molecular mechanism for decreased exercise capacity. Proc Natl Acad Sci U S A 105:2198–2202PubMedCrossRef
46.
go back to reference Palmieri F (2004) The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflugers Arch 447:689–709PubMedCrossRef Palmieri F (2004) The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflugers Arch 447:689–709PubMedCrossRef
47.
go back to reference Momken I, Lechêne P, Koulmann N et al (2005) Impaired voluntary running capacity of creatine kinase-deficient mice. J Physiol 15:951–964CrossRef Momken I, Lechêne P, Koulmann N et al (2005) Impaired voluntary running capacity of creatine kinase-deficient mice. J Physiol 15:951–964CrossRef
48.
go back to reference Reggiani C, te Kronnie T (2006) RyR isoforms and fibre type-specific expression of proteins controlling intracellular calcium concentration in skeletal muscles. J Muscle Res Cell Motil 27:327–335PubMedCrossRef Reggiani C, te Kronnie T (2006) RyR isoforms and fibre type-specific expression of proteins controlling intracellular calcium concentration in skeletal muscles. J Muscle Res Cell Motil 27:327–335PubMedCrossRef
Metadata
Title
Constitutive expression of suppressor of cytokine signalling-3 in skeletal muscle leads to reduced mobility and overweight in mice
Authors
P. Lebrun
E. Cognard
R. Bellon-Paul
P. Gontard
C. Filloux
C. Jehl-Pietri
P. Grimaldi
M. Samson
L. Pénicaud
J. Ruberte
T. Ferre
A. Pujol
F. Bosch
E. Van Obberghen
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1474-9

Other articles of this Issue 10/2009

Diabetologia 10/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.